Department of Oncology, University Hospital Ostrava, 17. listopadu 1790, 70852, Ostrava, Czech Republic.
Strahlenther Onkol. 2012 Aug;188(8):666-70. doi: 10.1007/s00066-012-0128-x. Epub 2012 Jun 1.
The present study was performed to evaluate the feasibility of a new, 5-week regimen of 70-75 Gy hyperfractionated accelerated radiotherapy with concomitant integrated boost (HARTCIB) for locally advanced, inoperable head and neck cancer.
A total of 39 patients with very advanced, stage IV nonmetastatic head and neck squamous cell carcinoma (median gross tumor volume 72 ml) were included in this phase I dose escalation study. A total of 50 fractions intensity-modulated radiotherapy (IMRT) were administered twice daily over 5 weeks. Prescribed total dose/dose per fraction for planning target volume (PTV(tumor)) were 70 Gy in 1.4 Gy fractions, 72.5 Gy in 1.45 Gy fractions, and 75 Gy in 1.5 Gy fractions for 10, 13, and 16 patients, respectively. Uninvolved lymphatic nodes (PTV(uninvolved)) were irradiated with 55 Gy in 1.1 Gy fractions using the concomitant integrated boost.
Acute toxicity was evaluated according to the RTOG/EORTC scale; the incidence of grade 3 mucositis was 51% in the oral cavity/pharynx and 0% in skin and the recovery time was ≤ 9 weeks for all patients. Late toxicity was evaluated in patients in complete remission according to the RTOG/EORTC scale. No grade 3/4 late toxicity was observed. The 1-year locoregional progression-free survival was 50% and overall survival was 55%.
HARTCIB (75 Gy in 5 weeks) is feasible for patients deemed unsuitable for chemoradiation. Acute toxicity was lower than predicted from radiobiological models; duration of dysphagia and confluent mucositis were particularly short. Better conformity of radiotherapy allows the use of more intensive altered fractionation schedules compared with older studies. These results suggest that further dose escalation might be possible when highly conformal techniques (e.g., stereotactic radiotherapy) are used.
本研究旨在评估新的 5 周 70-75Gy 超分割加速放疗联合同期整合推量(HARTCIB)治疗局部晚期、不可手术的头颈部癌的可行性。
共纳入 39 例非常晚期的、IV 期非转移性头颈部鳞状细胞癌患者(中位大体肿瘤体积 72ml),进行这项 I 期剂量递增研究。5 周内每天两次共进行 50 次调强放疗(IMRT)。计划靶区(PTV(肿瘤))的总剂量/分次剂量分别为 70Gy/1.4Gy、72.5Gy/1.45Gy 和 75Gy/1.5Gy,分别用于 10、13 和 16 例患者。未受累的淋巴结(PTV(未受累))采用同期整合推量以 1.1Gy/次照射 55Gy。
根据 RTOG/EORTC 标准评估急性毒性;口腔/咽的 3 级黏膜炎发生率为 51%,皮肤为 0%,所有患者的恢复时间均≤9 周。根据 RTOG/EORTC 标准,在完全缓解的患者中评估迟发性毒性。未观察到 3/4 级迟发性毒性。1 年局部区域无进展生存率为 50%,总生存率为 55%。
HARTCIB(75Gy/5 周)对头颈部放化疗不适合的患者是可行的。急性毒性低于基于放射生物学模型的预测;吞咽困难和弥漫性黏膜炎的持续时间特别短。放疗的更好适形性允许与旧研究相比采用更强化的分割方案。这些结果表明,当使用高适形技术(如立体定向放疗)时,可能进一步提高剂量。